CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS $ in Thousands	6 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)
Operating activities
Net loss	$ (28,193)	$ (37,733)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation and amortization	859	1,177
Amortization and accretion on investment securities, net	(933)	(1,092)
Future royalty payment contingency interest accretion	1,273	1,118
Share-based compensation	10,604	13,285
Loss on disposal of property and equipment	34	1,352
Loss on impairment of long-lived assets	2,951
Amortization of right-of-use assets	2,232	1,817
Deferred income taxes	(1,074)
Changes in operating assets and liabilities:
Receivables from collaborative and licensing arrangements	3,175	989
Prepaid clinical and development services	(608)	533
Other prepaid and current assets	5,318	(95)
Right-of-use lease assets	(548)	(144)
Other assets	292	1,751
Accounts payable	182	83
Accrued personnel-related expenses, accrued clinical and development expenses, and other accrued liabilities	(2,256)	(6,534)
Deferred revenue		(11)
Operating lease liabilities	(2,498)	(479)
Unrecognized tax benefits	3,714
Other long-term liabilities	39	326
Net cash used in operating activities	(5,437)	(23,657)
Investing activities
Purchases of property and equipment	(127)	(1,790)
Purchases of marketable securities	(58,140)	(134,534)
Maturities of marketable securities	72,264	31,435
Sale of short-term investments and marketable securities		71,377
Proceeds from the sale of property and equipment		1,513
Net cash provided by (used in) investing activities	13,997	(31,999)
Financing activities
Ordinary share repurchases	(445)	(135,896)
Proceeds from the sale of ordinary shares	44
Proceeds from ESPP purchases	375	446
Repurchase of shares to satisfy tax withholding	(1,734)	(1,470)
Net cash used in financing activities	(1,760)	(136,920)
Net increase (decrease) in cash, cash equivalents, and restricted cash	6,800	(192,576)
Cash, cash equivalents, and restricted cash at beginning of period	40,381	299,008
Cash, cash equivalents, and restricted cash at end of period	47,181	106,432
Supplemental disclosure of cash flow information
Cash paid for income taxes, net	$ 12	14
Supplemental disclosure of non-cash activities
Recognition of tenant improvement allowance assigned to sublease		$ 6,490